Biocon Limited — Important, 07-01-2025: Updates

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Biocon Biologics’ Ustekinumab BS, a biosimilar to J&J's Stelara®, for treating Psoriasis Vulgaris and Psoriatic Arthritis. Biocon, through its exclusive partner Yoshindo Inc., will market this product in Japan. This approval follows a previous licensing agreement with Janssen Biotech Inc. to commercialize Ustekinumab in the region upon receiving regulatory clearance. This development presents a significant growth opportunity for Biocon Biologics, positioning it well in the biopharmaceutical market and reinforcing its capabilities in biosimilars. Investors should watch closely for commercialization progress and market penetration.